Market Intelligence, Clinical Progress, and High-Purity Reagents for Oculopharyngeal Muscular Dystrophy (OPMD) and RNA-Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PABPN1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PABPN1 Recombinant Protein (Wild-Type & OPMD Polyalanine Expansion Mutant; e.g., 17Ala). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View PABPN1 Products |
| Gene Delivery | PABPN1 Lentivirus Particles (Promise-ORF). Full-length ORF with intact nuclear localization signal for stable cell lines. HEK293 expressed. | View PABPN1 Products |
| Benchmark Antibody | Anti-PABPN1 Recombinant Antibody. Research-grade positive control for WB, IF, and IP. | View PABPN1 Products |
| Validator | PABPN1 siRNA Set. For knockdown verification and specificity controls. | View PABPN1 Products |
| Related Target: PABPC1 | PABPC1. Cytoplasmic poly(A) binding partner; functional homolog and off-target liability counter-screen. | View PABPC1 Products |
| Related Target: CPSF4 | CPSF4 (CFIm). Cleavage factor involved in alternative polyadenylation; pathway partner for combinatorial studies. | View CPSF4 Products |
| Related Target: CPSF6 | CPSF6. Core 3' end processing factor; direct polyadenylation complex interactor. | View CPSF6 Products |
| Related Target: CPSF1 | CPSF1. Cleavage and polyadenylation specificity factor complex member. | View CPSF1 Products |
| Related Target: PAPOLA | PAPOLA (Poly(A) Polymerase Alpha). Enzymatic partner in poly(A) tail synthesis; essential for coupled activity assays. | View PAPOLA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pathogenic mutant aggregation & insolubility | Proprietary refolded monomeric mutant supplied in activity-ready buffer; purity >95%; aggregate depleted by preparative ultracentrifugation. Both WT and expanded polyalanine tract variants (aggregation-competent conformations preserved) available. |
| Nuclear delivery & stable expression validation | HEK293 Expressed Lentivirus with full-length ORF and intact NLS; native nuclear localization; endotoxin controlled for cell-based assays. |
| WT vs Mutant selectivity screening | Matched WT and mutant (e.g., 17Ala-expansion) pair with identical N-terminal tags and buffer formulation for direct comparative SPR/BLI. |
| RNA-binding domain integrity | RRM domains verified by CD spectroscopy; functional RNA-binding confirmed by EMSA compatibility. |
| Off-target screening (PABP family) | PABPC1/PABPC4 ortholog proteins available for selectivity profiling. |
| Lack of specific controls & false positives | Sequence-verified benchmark antibody plus validated siRNA set included for knockdown rescue and specificity confirmation. |
Live PABPN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PABPN1 therapeutics is intensifying. Oculopharyngeal Muscular Dystrophy (OPMD), caused by GCG trinucleotide repeat expansions leading to polyalanine tract elongation and nuclear aggregation, remains the primary indication. Major players are shifting focus from traditional gene therapy to targeted antisense oligonucleotides (ASOs), antibody-oligonucleotide conjugates (AOCs), and small-molecule disruptors of pathogenic aggregation. First-generation allele-specific silencers (e.g., Benitec Biopharma's BB-301 using a "silence and replace" strategy with AAV vector) are reaching preclinical and early clinical milestones. The next wave of R&D targets enhanced nuclear delivery systems, autophagy-inducing combination therapies, and mutant-selective degradation to clear PABPN1 aggregates in skeletal muscle.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO / siRNA | Academic consortia, Ionis (peripheral programs), specialty rare-disease biotechs | OPMD, distal myopathy | Allele-selective knockdown validation (Need WT vs Mutant protein standards and siRNA sets) |
| AOC (Antibody-Oligonucleotide Conjugate) | Avidity Biosciences (platform), Biogen | OPMD, Myotonic Dystrophy | Nuclear uptake assays (Need full-length NLS-intact protein for binding) |
| Small Molecule (Aggregation inhibitors) | Early-discovery platform companies, academic drug discovery | OPMD, oncology (emerging) | Aggregation inhibition and RNA-binding assays (Need monomeric recombinant WT and aggregation-competent mutant PABPN1) |
| Gene Therapy (AAV-based) | Benitec Biopharma, Sarepta Therapeutics (peripheral), Lacerta Therapeutics | OPMD | Expression and biodistribution validation; "silence and replace" efficacy (Need ORF lentivirus, benchmark antibodies, and high-purity antigens) |